EU/3/18/1972

Table of contents

About

On 22 February 2018, orphan designation (EU/3/18/1972) was granted by the European Commission to CATS Consultants GmbH, Germany, for 1-[[[4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-6-methoxyquinolin-7-yl]oxy]methyl]cyclopropanamine-dihydrochloride (also known as AL3818 and anlotinib) for the treatment of soft tissue sarcoma.

Key facts

Active substance
1-[[[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-6-methoxyquinolin-7-yl]oxy]methyl]cyclopropanamine-dihydrochloride
Disease / condition
Treatment of soft tissue sarcoma
Date of decision
22/02/2018
Outcome
Positive
Orphan decision number
EU/3/18/1972

Sponsor's contact details

CATS Consultants GmbH
Ussenried 7
87463 Dietmannsried
Germany
Tel. +49 8374 480
E-mail: adriaan@catsconsultants.com; judyc@advenchen.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating